文献速递关节外科骨肿瘤

多发性骨髓瘤患者全髋与全膝关节置换术后的结局

Postoperative Outcomes in Total Hip and Total Knee Arthroplasty for Patients Who Have Multiple Myeloma.
PubMed 文献 · J Arthroplasty · 2023-05-20

本研究基于机构数据库纳入2000至2021年间术前诊断为多发性骨髓瘤的104例患者(78例全髋、26例全膝),评估术前因素对假体生存的影响。全髋翻修9例(11.5%),感染、假体周围骨折和不稳定为主要指征;接受放疗者翻修风险更高(OR 6.551)。全膝翻修1例(3.8%),未发现失败预测因素。

要点

  • 多发性骨髓瘤患者全髋翻修率11.5%,全膝翻修率3.8%。
  • 全髋翻修最常见指征为感染(33.3%)、假体周围骨折(22.2%)和不稳定(22.2%)。
  • 接受放疗者需翻修全髋的风险更高(OR 6.551,95%CI 1.148-53.365,P=0.045)。

核心结论

  • 骨科医生应知晓多发性骨髓瘤患者翻修风险相对较高,尤其是全髋置换术后。
  • 应在术前识别存在失败风险因素的患者以避免不良结局。

研究设计与样本

  • 回顾性比较研究(证据等级III),利用机构数据库纳入2000至2021年间术前诊断为多发性骨髓瘤并行初次关节置换的104例患者(78例全髋,26例全膝)。

主要发现

  • 全髋翻修9例(11.5%),平均翻修时间1,312天(范围14至5,763天),感染占33.3%、假体周围骨折占22.2%、不稳定占22.2%;其中3例(33.3%)接受多次翻修手术。
  • 全膝翻修1例(3.8%),于术后74天因感染行翻修。
  • 接受放疗者需行全髋翻修的可能性更高(OR 6.551,95%CI 1.148-53.365,P=0.045);全膝患者未发现失败预测因素。

关键数值与推荐

  • 全髋翻修率11.5%(9/78),全膝翻修率3.8%(1/26)。
  • 放疗与全髋翻修风险相关(OR 6.551,95%CI 1.148-53.365,P=0.045)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advancements in oncologic care have increased the longevity of patients who have multiple myeloma, although outcomes beyond the early postoperative period following total hip arthroplasty (THA) and total knee arthroplasty (TKA) remain unknown. This study investigated the influence of preoperative factors on implant survivorship following THA and TKA after a minimum 1-year interval for multiple myeloma patients. METHODS: Using our institutional database, we identified 104 patients (78 THAs, 26 TKAs) from 2000 to 2021 diagnosed with multiple myeloma before their index arthroplasty by International Classification of Diseases, Ninth and Tenth Revisions (ICD-9 and ICD-10) codes 203.0× and C90.0× and corresponding Current Procedural Terminology (CPT) codes. Demographic data, oncologic treatments, and operative variables were collected. Multivariate logistic regressions assessed variables of interest, and Kaplan-Meier curves were used to estimate implant survival. RESULTS: There were 9 (11.5%) patients who underwent revision THA after an average time of 1,312 days (range, 14 to 5,763), with infection (33.3%), periprosthetic fracture (22.2%), and instability (22.2%) being the most common indications. Of these patients, 3 (33.3%) underwent multiple revision surgeries. There was 1 (3.8%) patient who underwent revision TKA at 74 days postoperatively for infection. Patients treated with radiotherapy were more likely to require revision THA (odds Rratio (OR): 6.551, 95% confidence interval (CI): 1.148-53.365, P = .045), but no predictors of failure were identified for TKA patients. CONCLUSION: Orthopaedic surgeons should know that multiple myeloma patients have a relatively high risk of revision, particularly following THA. Accordingly, patients who have risk factors for failure should be identified preoperatively to avoid poor outcomes. LEVEL OF EVIDENCE: Level III, retrospective comparative study.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Salimy MS, Blackburn AZ, Alpaugh K, et al. Postoperative Outcomes in Total Hip and Total Knee Arthroplasty for Patients Who Have Multiple Myeloma. J Arthroplasty. 2023. PMID: 37211290. doi:10.1016/j.arth.2023.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。